Mustbio
June 18, 2025
Company Presentation
Oncology
153C
Mustbio develops first-in-class and best-in-class, highly tumor-selective immuno-cytokines. Our mission is to precisely harness the power of the immune system, addressing the limitations of conventional cytokine therapies with their narrow safety margins and overcoming the challenges posed by immunotherapies that are ineffective in cold tumors.
Company HQ City:
Suwon-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2021
Lead Product in Development:
MB5029 (aPD-1/IL-2v)
CEO
Maengsup Kim
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
What is your next catalyst (value inflection) update?
2025.09
Website
www.mustbio.com
Primary Speaker
.jpg)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}